Consolidated revenue of the company grew 16 percent year-on-year (Y-o-Y) to Rs.2,668 crore in quarter ended September 2013, supported by formulations business and strong growth US, Europe and Africa, the company said in a release.
"Despite challenges in markets like India, we have had a good first half, driven by strong business growth from markets like US and improved operational efficiencies... This consistent performance has led to a sustained EBIDTA and PAT improvement," Nilesh Gupta, managing director, said.
Consolidated earnings before interest, tax, depreciation and amortisation (EBITDA) climbed 27.9 percent Y-o-Y to Rs.660 crore and operating profit margin expanded 230 basis points Y-o-Y to 24.7 percent in the quarter gone by.
Formulations business of the company grew 17 percent while Active pharmaceutical ingredient or API (drug raw material) shot up 20 percent Y-o-Y.
No comments:
Post a Comment